In a phase 2 trial of 128 patients with AML in first remission receiving high-dose cytarabine, adding motixafortide did not substantially change median relapse-free survival vs placebo (10.3 vs 11.5 months; P=.98). Exploratory: effect may vary with CXCR4 expression.
RCTn = 128
Ceran et al. Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation